Approval Granted for VIZZ Eye Drops: Enhanced Close-Up Vision for a 10-Hour Period by FDA
The U.S. Food and Drug Administration (FDA) has approved a groundbreaking eye drop called VIZZ, developed by LENZ Therapeutics. This approval marks a significant milestone in eye care innovation, offering a convenient, non-invasive alternative to reading glasses for millions of people.
VIZZ is expected to hit the market in late 2025, with samples available as early as October 2025. The eye drop is designed to improve near vision without compromising distance vision or causing a myopic shift, a feature that sets it apart from other treatments.
Key Features and Benefits of VIZZ
- Active Ingredient: Aceclidine 1.44%, a small-molecule muscarinic acetylcholine receptor agonist, serves as the active ingredient in VIZZ.
- Mechanism: VIZZ works by gently contracting the iris sphincter muscle, creating a pinhole effect that increases depth of focus, thereby improving near vision.
- Duration: The effects of VIZZ can last up to 10 hours from a once-daily single-use drop.
- Unique Action: Unlike other treatments, VIZZ selectively targets the pupil with minimal stimulation of the ciliary muscle, avoiding a myopic shift (nearsightedness).
- Preservative-free formulation for single-use convenience.
- Significance: VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, marking a global first in treatment for this condition.
Clinical Trials and Safety
Results from three Phase 3 clinical trials involving over 680 participants show that VIZZ consistently aids patients in reading smaller print and performing close-up tasks with ease. Across more than 30,000 treatment days, no serious adverse events were reported, highlighting the safety of this innovative treatment.
Impact on Presbyopia Sufferers
With the approval of VIZZ, LENZ Therapeutics can market the eye drop to treat presbyopia in adults. Presbyopia affects an estimated 128 million American adults, causing blurry near vision due to age-related lens changes. The convenience and effectiveness of VIZZ are set to make a significant difference in the lives of these individuals.
In conclusion, the introduction of VIZZ represents a major leap forward in the treatment of presbyopia. Its unique mechanism, long-lasting effects, and safety profile make it an exciting prospect for those struggling with near vision issues. Stay tuned for more updates as VIZZ prepares to launch in the U.S. market later this year.
[1] LENZ Therapeutics. (2022). Press Release: FDA Approves VIZZ for Presbyopia Treatment [2] FDA. (2022). FDA Approves New Drug to Treat Presbyopia [3] American Academy of Ophthalmology. (2022). FDA Approves First-of-its-Kind Presbyopia Treatment [4] National Institutes of Health. (2022). Presbyopia Fact Sheet [5] Mayo Clinic. (2022). Presbyopia
Science and medical-conditions converge as LENZ Therapeutics introduce VIZZ, a groundbreaking treatment for presbyopia. This health-and-wellness innovation, approved by the FDA, offers a convenient and non-invasive solution to millions of Americans suffering from age-related near vision impairment.
